(ASX:PAB) says new preclinical data from the Garvan Institute of Medical Research has shown that its’ deoxymab antibody PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer.
The study, conducted by Associate Professor Marina Pajic, showed that twice-weekly treatment with PAT-DX1 for four weeks significantly reduced the growth of pancreatic tumours by 26 per cent and increased median survival by 47 per cent.
Pancreatic cancer remains one of the most challenging cancers to treat, with fewer than 25 per cent of patients surviving their first year after diagnosis.
Patrys said deoxymabs have natural tumour targeting qualities, allowing them to bind to DNA and disrupt the tumour’s intracellular DNA Damage Repair systems. “This makes them a promising candidate for a range of hard to treat cancers,” it said.
According to CEO and managing director Dr James Campbell, “The demonstration that PAT-DX1 is able to inhibit growth and improve survival in an animal model of pancreatic cancer validates the approach we are taking with our deoxymab antibody platform.
“We recently reported on the ability of PAT-DX1 to cross the blood-brain barrier and treat both primary and secondary brain cancers. This new data from Garvan reinforces that Patrys’ deoxymabs may also have clinical utility for the treatment of non-brain cancers as well.
“We believe the combination of natural tumour targeting with blocking DNA Damage Repair that Patrys’ deoxymabs offer provides a unique and very powerful approach for tackling difficult-to-treat cancers. On the back of this exciting data, we look forward to continuing our work with Associate Professor Pajic evaluating the potential of both PAT-DX1 and PAT-DX3 as new, potent treatments for pancreatic cancer.”
Associate Professor Pajic said, “The initial data that we have seen from testing Patrys’ deoxymabs in animal models of pancreatic cancer are very encouraging. We believe that the novel mechanism of action of deoxymabs may make them amenable to a range of possible therapeutic applications and we look forward to exploring these further with the Patrys team.”